Literature DB >> 19330729

Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease.

Nevin Oruç1, Omer Ozütemiz, Necla Osmanoğlu, Tankut Ilter.   

Abstract

BACKGROUND/AIMS: Procalcitonin and C-reactive protein are two acute-phase reactant proteins, although procalcitonin is a more specific marker for bacterial infections. Procalcitonin level might also be helpful to predict the disease activity of inflammatory bowel disease. This study aimed to compare the diagnostic value of serum procalcitonin and C-reactive protein as indicators of disease activity in inflammatory bowel disease.
METHODS: Patients admitted to the inflammatory bowel disease inpatient clinic with suspected inflammatory bowel disease who had not yet been treated with immunosuppressive treatments were included. Disease activity, white blood cell count, sedimentation rate, serum procalcitonin and C-reactive protein levels were evaluated in 45 newly diagnosed inflammatory bowel disease patients (9 Crohn's disease and 36 ulcerative colitis). Fifty healthy volunteers were analyzed as a control group.
RESULTS: Crohn's disease patients had higher procalcitonin and C-reactive protein levels than healthy controls (Procalcitonin: 0.143+/-0.081 vs. 0.065+/-0.008 ng/ml, p<0.05; C-reactive protein: 29+/-7.5 vs. 2.9+/-0.5 mg/dl, p<0.001, respectively). Ulcerative colitis patients also had slightly higher procalcitonin levels and significantly higher C-reactive protein levels than controls (Procalcitonin: 0.107+/-0.042 ng/ml; C-reactive protein: 23+/-5.5 mg/dl). Two Crohn's disease patients had procalcitonin value above 1 ng/ml. Receiver operating characteristic curve analysis demonstrated that C-reactive protein is the best marker of disease activity in inflammatory bowel disease while procalcitonin has low sensitivity and specificity. Serum procalcitonin levels were highly correlated with serum C-reactive protein but no other disease activity parameters.
CONCLUSIONS: Although still within normal ranges, procalcitonin levels were slightly elevated in Crohn's disease but not in ulcerative colitis patients compared to healthy controls. Serum C-reactive protein is a reliable marker for disease activity in inflammatory bowel disease. Procalcitonin has no diagnostic value in determining disease activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330729

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  6 in total

1.  Clinical importance of serum procalcitonin in ulcerative colitis patients.

Authors:  Ergenekon Karagoz; Alpaslan Tanoglu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

2.  Differentiating Clostridium difficile Colitis from Clostridium difficile Colonization in Ulcerative Colitis: A Role for Procalcitonin.

Authors:  Andrew R Reinink; Julajak Limsrivilai; Bethany A Reutemann; Tristan Feierabend; Emily Briggs; Krishna Rao; Peter D R Higgins
Journal:  Digestion       Date:  2017-10-14       Impact factor: 3.216

3.  Clinical significance of serum procalcitonin in patients with ulcerative colitis.

Authors:  Shigeo Koido; Toshifumi Ohkusa; Kazuki Takakura; Shunichi Odahara; Shintaro Tsukinaga; Toyokazu Yukawa; Jimi Mitobe; Mikio Kajihara; Kan Uchiyama; Hiroshi Arakawa; Hisao Tajiri
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

4.  Usefulness of Measuring Serum Procalcitonin Levels in Patients with Inflammatory Bowel Disease.

Authors:  Sook Hee Chung; Hye Won Lee; Seung Won Kim; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Gut Liver       Date:  2016-07-15       Impact factor: 4.519

Review 5.  Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities.

Authors:  Giuseppe Lippi; Fabian Sanchis-Gomar
Journal:  World J Gastroenterol       Date:  2017-12-21       Impact factor: 5.742

6.  Prognostic value of assessment of stool and serum IL-1β, IL-1ra and IL-6 concentrations in children with active and inactive ulcerative colitis.

Authors:  Andrzej Wędrychowicz; Przemysław Tomasik; Andrzej Zając; Krzysztof Fyderek
Journal:  Arch Med Sci       Date:  2017-06-30       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.